The FDA has approved a new HIV prevention drug that is administered every two months via injection.


The FDA has approved a new HIV prevention drug that is administered every two months via injection.

The Food and Drug Administration (FDA) has approved a new HIV prevention drug that many patients may find easier to take.

Apretude is a new drug that is administered twice a year by injection.

It could be used instead of daily pills, which are difficult to remember to take and have a low uptake among some at-risk groups.

In clinical trials, patients who took Apretude had a 69 percent lower risk of HIV infection compared to those who took daily pills, and a 90 percent lower risk compared to those who took daily pills.

The new drug could be a great option for people who are at high risk of contracting HIV, but potential patients may face access issues because it must be given in a medical setting.

Existing HIV prevention drugs are disproportionately used by white people, as opposed to black and Hispanic or Latino Americans, who make up a larger proportion of the high-risk population.

While the COVID-19 pandemic has dominated healthcare in the United States for the past two years, the HIVAIDS epidemic continues to affect tens of thousands of people.

The human immunodeficiency virus (HIV) attacks the immune system of the body.

If left untreated, it can progress to AIDS (acquired immune deficiency syndrome).

The virus primarily affects LGBTQ(+) people, as well as black and Hispanic people in the United States.

Despite the fact that HIV is treatable, the CDC advises people in high-risk groups to take preventative measures to avoid becoming infected in the first place.

The FDA approved a new HIV prevention drug on Monday, which could be a better option for many of these people.

Patients are given this new drug, called Apretude, in the form of a blood injection every two months.

Viiv Healthcare, a pharmaceutical company based in North Carolina and owned by GlaxoSmithKline, created Apretude.

In a statement, Dr. Debra Birnkrant, director of the FDA’s Center for Drug Evaluation and Research, said, “Today’s approval adds an important tool in the effort to end the HIV epidemic by providing the first option to prevent HIV that does not involve taking a daily pill.”

‘This injection, given every two months, will be critical in combating the HIV epidemic in the United States, including assisting high-risk individuals and certain groups for whom adherence to daily medication has been difficult or impossible.’

For many patients, the new drug may be able to take the place of a daily pill regimen.

Only 25% of the 1.2 million people who have been advised to take PrEP pills will do so by 2020…

Nokia News in a Nutshell


Comments are closed.